Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide after hepatectomy for recurrence prevention in hepatocellular carcinoma
ChiCTR-TRC-13003244Phase 4Completed
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of arsenic trioxide in hepatocellular carcinoma (HCC) (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoints: Overall survival, Disease-free survival and 2 more. Started Jun 2013; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-13003244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003244.